Out of the Frying Pan and Into the Clinic | GenomeWeb

In 10 years, NHGRI hopes to take DNA sequencers from the lab to the clinic, but some companies think 10 years isn't soon enough, says Forbes' Matthew Herper. Illumina's Jay Flatley has already talked about getting regulatory approval "to use his technology for medical purposes," Herper says. And even though regulatory approval — whether of the sequencers themselves or the interpretation of the sequence is unclear — is only the first hurdle.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

Changes Ahead

To Spot it Early

Promising Trial

And, Poof, It's Gone

Cancer Trial Halted

Market Creator

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.